Q-omics provides the consensus-scored SPC24 profile across patient tissues and cancer cell-line models. SPC24 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPC24 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SPC24 protein abundance shows 28,252 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where SPC24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPC24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPC24 survival associations across molecular data types. SPC24 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPC24 RNA expression–survival associations across cancer types. High SPC24 expression shows unfavorable associations in ACC, KIRC, KIRP, MESO, KICH and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPC24 RNA expression.
This table summarizes SPC24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPC24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPC24 shows higher tumor expression in HNSC, COAD, KIRC, KIRP, LUAD and BLCA. The HNSC box plot shows higher SPC24 RNA expression in tumor versus normal tissue (log2 FC = +1.937, t-test p < 0.001).
This table shows molecular features associated with SPC24 in patient tissues and cancer cell lines. In patient samples, SPC24 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPC24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
